Search: L773:1684 1182 OR L773:1995 9133 >
Molnupiravir for th...
Molnupiravir for the treatment of COVID-19 outpatients : An updated meta-analysis
-
Cheema, H. A. (author)
-
Abdul Rab, S. (author)
-
Butt, M. (author)
-
show more...
-
Jafar, U. (author)
-
Shahid, A. (author)
-
Rehman, A. U. (author)
-
- Lee, Ka Yiu (author)
- Mittuniversitetet,Institutionen för hälsovetenskaper (HOV),Swedish Winter Sports Research Centre
-
Sahra, S. (author)
-
Sah, R. (author)
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2024
- 2024
- English.
-
In: Journal of Microbiology, Immunology and Infection. - : Elsevier BV. - 1684-1182. ; 57:3, s. 396-402
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://miun.diva-po... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: The majority of available data on molnupiravir come from an unvaccinated COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence from recent randomized controlled trials (RCTs) as well as observational studies stratified by vaccination status to determine the clinical efficacy and safety of molnupiravir in COVID-19 outpatients. Methods: We searched PubMed, Embase, the Cochrane Library, medRxiv, and ClinicalTrials.gov from inception to November 2023. We conducted our meta-analysis using RevMan 5.4 with risk ratio (RR) as the effect measure. Results: We included 8 RCTs and 5 observational studies in our meta-analysis. Molnupiravir reduced the risk of all-cause mortality (RR 0.28; 95% CI: 0.20–0.79, I2 = 0%) but did not decrease the hospitalization rate (RR 0.67; 95% CI: 0.45–1.00, I2 = 53%) in the overall population; in the immunized population, no benefits were observed. Molnupiravir lowered the rate of no recovery (RR 0.78; 95% CI: 0.76–0.81, I2 = 0%) and increased virological clearance at day 5 (RR 2.68; 95% CI: 1.94–4.22, I2 = 85%). There was no increase in the incidence of adverse events. Conclusions: Molnupiravir does not decrease mortality and hospitalization rates in immunized patients with COVID-19. However, it does shorten the disease course and increases the recovery rate. The use of molnupiravir will need to be considered on a case-by-case basis in the context of the prevailing social circumstances, the resource setting, drug costs, and the healthcare burden.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Public Health, Global Health, Social Medicine and Epidemiology (hsv//eng)
Keyword
- COVID-19
- EIDD-2801
- MK-4482
- Molnupiravir
- SARS-CoV-2
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database